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Infiltration of effector CD8 T cells plays a major role in allograft rejection, and increases 
in memory and terminally differentiated effector memory CD8 T cells are associated 
with long-term allograft dysfunction. Alternatively, CD8 regulatory T cells suppress the 
inflammatory responses of effector lymphocytes and induce allograft tolerance in animal 
models. Recently, there has been a renewed interest in the field of immunometabolics 
and its important role in CD8 function and differentiation. The purpose of this review is to 
highlight the key metabolic pathways involved in CD8 T cells and to discuss how manip-
ulating these metabolic pathways could lead to new immunosuppressive strategies for 
the transplantation field.
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inTRODUCTiOn
To efficiently protect mammalian against pathogen infection, the response of the adaptive T-cell 
immune system follows a three-step process: an initial phase of T-cell priming followed by a massive 
clonal expansion and differentiation, a contraction phase leading to the clearance of most effector 
cells, and the generation of memory immune T cells. Numerous subsets of memory CD8 T cells 
have been described with different functions and localization within the body. Seminal study by 
Sallusto et al. identified that isoform CD45RA and lymph node homing marker CCR7 allow the dis-
crimination of naive and subsets of memory CD8 cells (central memory, CM; effector memory, EM; 
terminally differentiated effector memory cells, TEMRA) (1). The inclusion of additional markers, 
such as CD27, CD28, CD57, or TBET, can narrow down the identification of specific memory subsets 
to decipher their relative function during the recall response and to identify checkpoint regulating 
their differentiation and their survival (2). T-cell response to antigen stimulation and activating their 
effector functions are energetically demanding processes. Over the last decade, numerous reports 
have highlighted that the generation of effector and memory cells is not only regulated by the inflam-
matory milieu but also by metabolic processes.
In the 1920s, Otto Warburg observed that cancer cells consumed much higher amounts of glucose 
compared with normal cells and that cancer cells mainly utilize glycolysis over mitochondrial respira-
tion, even in the presence of oxygen (3, 4). This metabolic strategy, termed the Warburg effect, has also 
been observed in activated lymphocytes (5–7). Despite being less efficient albeit rapid at producing 
ATP, the aerobic glycolysis enables cells to generate the biosynthetic precursors necessary to support 
rapid growth and proliferation as well as to maintain the redox balance (8). The renewed interest 
in the metabolic processes involved in T-cell biology has also revealed that evolutionary conserved 
pathways, such as the mammalian target of rapamycin (mTOR) pathway, are common to both immune 
responses and metabolism regulation (9). The goal of this review is to summarize the link between 
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CD8 T-cell subsets and their metabolic adaptations and to evaluate 
how targeting this metabolic programming could be a new possi-
ble therapeutic treatment, with a special focus on transplantation.
T CeLL AnD TRAnSPLAnT OUTCOMe: 
KnOwn TARGeTS THAT ReQUiReD new 
THeRAPeUTiC TOOLS
Involvement of T lymphocytes in solid organ transplant rejection 
is a well-researched topic in the transplantation field; however, 
most of the research focuses on the various roles of the different 
CD4 lymphocyte subpopulations. Few investigate the role of CD8 
cells in transplantation with a main focus on their cytotoxic and 
proinflammatory functions and how deleterious they are to long-
term allograft health (10–13). In acute allograft rejection, infiltrat-
ing CD8 T cells play a major role in tubulitis and tissue necrosis. 
Cytotoxic molecules, such as perforin and granzyme-B, as well 
as proinflammatory cytokines, such as IFN-γ, secreted by CD8 T 
cells have been shown to contribute to the rejection response (14, 
15). Furthermore, memory CD8 T cells have been shown to act 
as major barriers for transplant tolerance induction protocols (16, 
17). Additionally, recent immunomonitoring research has shown 
that an increase in certain CD8 populations in transplant patients 
is associated with allograft rejection and loss. Elevated effector, 
memory, and TEMRA CD8 subsets in the peripheral circulation 
are associated with increased occurrence of acute and chronic 
allograft dysfunction (18–22). As a result, immunomodulation 
of the CD8 population is an important component for long-term 
allograft survival and targeting their specific metabolic processes 
could represent a new mean to foster graft survival.
There is budding interest into a small subpopulation of CD8 
lymphocytes with regulatory and suppressive functions. While 
most of the research has been focused on CD4+FOXP3+Tregs, 
there is growing interest in the other types of regulatory T cells, 
which include the CD8 Tregs (23–25). There have been several 
different nomenclatures proposed in the literature, which can 
be used to identify this subset of cells, a few examples being 
CD8+CD28−, CD8+CD45RClow, and CD8+FOXP3+ (26–28). CD8 
Treg populations have potent suppressive ability against effector 
lymphocytes and promote tolerant induction in rodent transplant 
models, thus making them an attractive target for promoting 
allograft survival (23, 24, 28–30). Immunometabolic regula-
tion of CD8 T cells could be used as a means to manipulate the 
CD8 T-cell immune function for effective immunosuppression. 
However, little is known regarding their metabolic adaptation 
during the induction and the expansion phases.
CD8 T-CeLL MeTABOLiC PROGRAMMinG 
CHAnGeS ARe SPeCiFiC TO CD8 
SUBSeTS AnD FUnCTiOn
Metabolic Demands in Quiescent T Cells
In resting state, naive T cells rely on oxidative phosphorylation 
(OXPHOS) to produce adenosine 5′-triphosphate (ATP) (31). 
This metabolic pathway is the most effective method to gener-
ate ATP by catabolizing metabolic intermediates derived from 
glucose, fatty acids, and amino acids. The low rate of energy 
metabolism needed by quiescent cells to maintain their house-
keeping functions is instructed by cytokine-dependent signals 
and preferentially IL-7-mediated signals. Indeed, IL-7 is a crucial 
cytokine to sustain the homeostasis of naive cells and their sur-
vival and is also an important regulator of the glucose transporter 
GLUT-1 (32). The IL-7 receptor (IL-7R) is largely expressed in 
naive lymphocytes and downregulated when naive CD8 T cells 
differentiate into the effector phenotype. IL-7 causes activation of 
JAK1 and JAK3, which in turn activates STAT5 and the PI3K/AKT 
pathways (32–34). IL-7 allows a basal glucose metabolism, which 
has been shown to be essential for quiescent T-cell survival (32).
In addition to mitochondrial glucose oxidation, resting T cells 
generate energy through the β-oxidation of fatty acids and espe-
cially quiescent memory subsets (Figure 1A). Fatty acid oxidation 
(FAO) is integral to the development of memory T cells, and when 
FAO is impeded, the memory CD8 T-cell population is heavily 
affected (35, 36). Pearce et al. showed that mice which lack tumor 
necrosis receptor-associated factor 6 (TRAF6) cannot upregulate 
FAO, and while these mice were able to mount a normal effector 
CD8 response, they were unable to form a CD8 memory population 
after bacterial infection (37). Additionally, TRAF6-deficient CD8 
cells could not properly activate AMP-activated kinase (AMPK); 
however, metformin, an AMPK activator, was able to rescue FAO 
in the TRAF6-deficient CD8 cells and promote the development 
of the memory subset (37). Interestingly, the fatty acids used are 
not acquired from their external environment. Instead, FAO is 
supported in memory T cells by the synthesis of triacylglycerols 
(TAGs) from externally acquired glucose. IL-7 has been shown to 
upregulate the expression of glycerol channel aquaporin 9 (AQP9) 
and increased TAG synthesis in antigen-experienced CD8 T cells. 
The resulting TAGs are hydrolyzed by lysosomal acid lipase into 
free fatty acids for FAO (36, 38). The generation of potent CD8 
memory T cells is also dependent on mTOR-related signaling 
since rapamycin, a mTOR inhibitor, promotes memory T-cell 
differentiation (39, 40). Rapamycin treatment during the CD8 
expansion phase has been shown to increase the resulting quantity 
of CD8 memory cells; furthermore, rapamycin given during the 
contraction phase results in memory CD8 cells that are highly 
functional and can mount a better memory response (39, 41, 42).
Activation of CD8 T Cells Leads to 
Metabolic Reprogramming
Proliferation and potent effector functions are an energetically 
demanding process that requires a metabolic adaptation in order 
to fulfill the needs of T cells. Upon activation, CD8 T cells repro-
gram their metabolism from OXPHOS to aerobic glycolysis and 
glutaminolysis (Figure 1B) (5). This glycolytic shift supports the 
rapid proliferation of activated lymphocytes not only in terms of 
energy requirement but also in terms of metabolic intermediates 
(43). These metabolic intermediates allow the biosynthesis of mac-
romolecules essential for the massive cell growth and proliferation 
required as effector CD8 cells expand during the immune response. 
For example, these intermediates generated from the glycolytic 
pathway are used to generate nucleotides, amino acids, and lipids, 
which in turn will be used to synthesize nucleic acids, lipids, and 
proteins needed in order to duplicate the cellular biomass (8, 43).
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FiGURe 1 | Metabolic pathways used by CD8 T cells in quiescent and active states. (A) When in a quiescent state, naive CD8 T cells fulfill their energy 
needs mainly through aerobic glycolysis and mitochondrial respiration. Fatty acid oxidation plays an important role during the restriction phase when effector CD8 
cells differentiate into memory CD8 cells and the immune system returns to a quiescent state. Memory T cells synthesized fatty triacylglycerols to supply fatty acids 
for fatty acid oxidation. (B) When stimulated, effector CD8 T cells rapidly upregulate glycolysis and glutaminolysis because the activated cells require many of the 
metabolic intermediates for macromolecule biosynthesis. The metabolic adaptations sustain the rapid expansion of effector CD8 T cells and support the secretion of 
cytokines and cytotoxic molecules.
FiGURe 2 | immunometabolic targets. This figure depicts the different metabolic and transcriptional pathways involved in the immunometabolic functions of CD8 
T cells. Black arrows are used to show the transport of glucose and glutamine into the cells where they are metabolized. The yellow arrow represents the combined 
signaling of the TCR and CD28 which activates CD8 effector cells and triggers the metabolic adaptations in the effector cells. The blue arrows show the 
transcriptional used by activated CD8 T cells to upregulate mTOR, which controls cellular metabolism and growth. Red arrows show the promotion or suppression 
of therapeutic molecules on the various immunometabolic pathways.
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T-cell activation requires two signals: one from the T-cell receptor 
(TCR) and the other from costimulatory receptors. TCR signaling 
alone is not sufficient for inducing major changes to the metabolic 
programming (44). The increased glucose metabolism seen in 
activated lymphocytes is due to CD28 costimulation signaling, 
which in turn activates the PI3K/AKT pathway (Figure 2) (44–46), 
leading to an increase of nutriment uptake, cell-surface expression, 
and function of glucose transporter. However, it is becoming appar-
ent that there are specific metabolic adaptations dependent on the 
T-cell subset. Gubser et al. showed that the effector memory CD8 
T cells are able to switch to glycolysis more rapidly as compared to 
naive CD8 T cells (47). Furthermore, effector memory CD8 T cells 
are able to sustain this higher glycolytic rate. Glycolysis has also 
been implicated in posttranscriptional control of cytokine secretion 
in activated lymphocytes. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) is an enzyme involved in the glycolytic process 
and has been shown to act as an mRNA-binding protein. Chang 
et  al. demonstrated that interferon-γ (IFNγ) secretion was sup-
pressed in activated lymphocytes which were cultured in galactose 
and thus could not utilize the glycolytic pathway. The depression 
in the IFNγ secretion is due to the binding of GAPDH to IFNγ 
transcripts. Therefore, glycolysis in lymphocytes has a secondary 
role as a regulator of GAPDH binding of IFNγ (48). The drastic 
diversion of energy generation from OXPHOS to aerobic glycolysis 
induced by T-cell activation may be oversimplified as a higher 
mitochondrial mass of memory CD8 T cells compared to naive 
CD8 T cells has been reported and linked to a higher enhancement 
of both OXPHOS and glycolysis in memory CD8 T cells (49).
In addition to increased glycolytic activity, activated T cells also 
upregulate glutamine metabolism (glutaminolysis). Glutamine, 
a common amino acid found in human plasma, can serve as 
an alternative source of energy. Activated lymphocytes require 
glutamine for cell proliferation and cytokine secretion, and CD28 
costimulation enhances glutamine uptake and increases glutamine 
transporter expression (50, 51). Several metabolic TCA cycle 
intermediates, such as citrate, α-ketoglutarate, and oxaloacetate, 
are crucial for proliferation as precursor for lipid and amino acids 
synthesis. Glutamine undergoes anaplerotic reaction to produce 
oxaloacetate and α-ketoglutarate metabolism through glutamate. 
Glutaminolysis also replenishes NADPH pool, which is also 
needed by proliferating lymphocytes to support lipid and nucleo-
tide biosynthesis as well as maintaining the redox balance (51, 52).
MeTABOLiC TARGeTS FOR 
iMMUnOMODULATinG CD8 T CeLLS
There are two possible approaches to manipulating the metabolic 
programming of CD8 cells as a means of immunosuppression for 
transplantation. The first would be to target metabolic pathways 
that are involved in cytokine production and cytotoxic activity of 
effector and effector memory cells in order to shut down CD8 T 
cells’ ability to cause damage to allografts (Figure 2). The other 
method would be to target metabolic pathways to enhance and 
promote the proliferation of CD8 Tregs, which will in turn cause 
a suppressive effect on the CD8 effector population, thus prolong-
ing allograft half-life and possibly favoring tolerance induction.
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Shutting Down the warburg effect in 
effector CD8 T Cells
As previously discussed, glycolysis and glutaminolysis are two 
key metabolic pathways that are imperative for proper CD8 
effector function. Finding methods to interrupt these pathways 
in allograft infiltrating effector cells would be a mean stopping 
allograft rejection. 2-Deoxy-d-glucose (2-DG) is a glucose 
analog that inhibits glycolysis by blocking hexokinase function. 
Many studies showed the potent effect of 2-DG in inhibiting the 
cytotoxic function of effector CD8 cells (47, 53–55). In a similar 
fashion, blocking glutaminolysis with a glutamine antagonist 
such as 6-diazo-5-oxo-l-norleucine (DON) inhibits lymphocyte 
proliferation (56). Additionally, blocking glucose and glutamine 
transporters disrupt lymphocyte activation and affect memory 
differentiation (57–60).
Targeting major bioenergetic pathways seems at first glance 
a rather dangerous means to control an immune response and 
major side effects such as a massive toxicity to normal tissue 
is expected. Animal models and ongoing therapeutic use of 
metabolic interferences therapies prove that such strategy is safe 
and feasible. For instance, leflunomide and its active metabolite 
teriflunomide prevent de novo biosynthesis of pyrimidine and 
efficiently inhibit the development of EAE (61). In multiple scle-
rosis patients, teriflunomide, compared to placebo, significantly 
reduces relapse rates, disability progression (at the higher dose), 
and MRI evidence of disease activity (62). Interestingly, whereas 
a link with metabolism has not been established, leflunomide 
or analogs have also been shown to be effective in prolonging 
graft survival and even to induce tolerance in a model of heart 
allograft transplantation (63). Metabolic interferences have 
been mainly studied in the cancer field. Given the similarity of 
metabolic adaptation between cancer cells and activated T cells, 
immunometabolic regulation of CD8 T cells could be used as 
a means to manipulate the CD8 T-cell immune function for 
effective immunosuppression. However, the doses required to 
eradicate all malignant cells and those required to control auto-or 
alloreactive T cells might be radically different. Cancer therapy 
aims to eradicate all cancer cells, whereas transplant therapy 
aims to control alloreactive T cells. Given their effector nature, 
alloreactive T cells are likely to be characterized by a higher use of 
glycolysis as compared to quiescent T cells. The selective targeting 
of glycolysis processes will thus focus preferentially alloreactive 
and not quiescent (naive or memory) T cells.
Targeting Transcriptional Regulators  
of immunometabolism
Since metabolic adaptation is required to support T-cell activa-
tion and function, nutrient availability or limitation will affect 
these processes. A recent publication has shown that adenosine 
monophosphate-activated protein kinase (AMPK) couples T-cell 
function to nutrient availability (64). AMPK is a serine-threonine 
kinase that is sensitive to energy levels and is activated during 
cellular stress. By sensing the AMP/ATP ratio, AMPK senses 
energy deficiency and favors pathways leading to ATP produc-
tion while inhibiting ATP-consuming pathway. It increases 
catabolic processes and inhibits anabolic processes to increase 
ATP production when activated. AMPK upregulates fatty acid 
β-oxidation by promoting the transfer of long-chain fatty acids 
into the mitochondria via carnitine palmitoyltransferase 1 (CPT1) 
(5). Metformin, a drug commonly used in diabetes treatment, 
blocks mitochondrial complex I, which has the downstream effect 
of promoting AMPK activity. Interestingly, metformin fosters 
memory CD8 T-cell differentiation in mice (37). In agreement 
with these results, it has been shown that autoreactive T cells can 
be efficiently controlled by the coadministration of 2-DG and 
metformin in a mouse model of systemic lupus erythematosus 
(SLE) (65). However, as meformin also inhibits OXPHOS, in vitro 
or in vivo administration is likely to have a broader target than 
solely the memory compartment.
The PI3K/AKT pathway is another key pathway that integrates 
immune stimulation and nutrient uptake (9). Blocking PI3K/
AKT pathway would therefore be another way to suppress the 
effector function of CD8 cells. The core kinases of this pathway 
are AKT, AMPK, and mTOR. An intimate positive and negative 
cross-regulation of these protein kinases has been shown  and this 
topic has been covered in-depth in several publications (5, 6, 9). 
AKT pathway is optimally activated by the coligation of TCR and 
CD28 and leads to the increase of glycolysis, via an increase of 
glucose uptake and the enhancement of rate-limiting glycolytic 
enzymes hexokinase and phosphofructokinase (66). Preventing 
activation of this pathway could be accomplished by inhibiting the 
costimulation signaling provided by CD28 or by directly inhibit-
ing AKT activity. FR104, an anti-CD28 antagonist antibody, has 
been shown to prevent lymphocyte activation and proliferation 
in a murine model (67). Furthermore, this drug has been shown 
to be effective in reducing allograft rejection in both murine and 
non-human primate models of transplantation (68, 69). Another 
possible strategy would be to target AKT directly through the use 
of one of the AKT inhibitors currently in development (70). For 
example, AKT inhibitor MK-2206 treatment in a murine model 
increased the differentiation of naive CD8 cells into central 
memory CD8 cells and diminished terminal differentiation in 
the CD8 population (71). Additionally, AKT can be modulated 
upstream by inhibiting focal adhesion kinase (FAK), a well-
established regulator of the PI3K/AKT pathway. Inhibiting FAK 
in Ewing sarcoma cells results in downregulation of both AKT 
and mTOR and impaired cell growth and colony formation (72, 
73). Donor lymphocyte infusions following allogeneic stem cell 
transplantation are performed to enhance the graft-versus-tumor 
(GVT) effect, and minor histocompatibility antigen (MiHA)-
specific CD8 T cells play an important role in this GVT response. 
It has been hypothesized that adoptive MiHA-specific CD8 T-cell 
transfer would lead to a more efficacious GVT response while also 
minimized graft-versus-host disease (GVHD), a harmful effect 
which is also observed in allogeneic stem cell transplant patients. 
AKT signal inhibition during ex vivo priming of naive precursor 
cells resulted in the generation of stem cell-like MiHA-specific 
CD8 T cells. Additionally, these cells have a superior proliferation 
capacity and antitumor effects in a murine model (74). While 
clinical research on these developmental AKT inhibitors has been 
mainly focused on the field of oncology and allogeneic stem cell 
transplantation, there could be possible use for them in the solid 
organ transplantation field.
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Boosting Treg Populations with Metabolic 
Programming
In the field of CD4 Tregs, there has been a lot of progress in 
finding viable ways to use them in clinical practices. Several 
clinical trials are currently in progress to evaluate the safety and 
efficacy of adoptive transfer of CD4 Tregs in allograft transplant 
recipients (75). However, studies concerning CD8 Tregs are at 
more exploratory stages.
Rapamycin is an antifungal macrolide that is produced by 
bacteria discovered on Easter Island which targets and inhibits 
mTOR and is already used as a part of immunosuppressive regi-
mens in transplantation. mTOR is a serine/threonine kinase that 
regulates cell survival, growth, and energy metabolism. mTOR 
can form two distinct complexes, mTOR complex 1 (mTORC1), 
which is rapamycin sensitive, and mTOR complex 2 (mTORC2), 
which is rapamycin insensitive and much less studied compared 
to mTORC1 (41, 76–79). mTORC1 is the master regulator of cell 
growth and metabolism and can be activated through either PI3K 
or AKT signaling. Upon activation, mTORC1 promotes ribosome 
biogenesis and increases protein translation and synthesis (6, 
78, 79). mTORC1 also promotes lipid biosynthesis and regulates 
mitochondrial metabolism and biogenesis through sterol regula-
tory element-binding proteins (SREBP) which are involved in 
positively regulating lipid homeostasis (80, 81). Rapamycin targets 
and inhibits mTOR activity, thus interfering with G1 phase cell 
cycle activity and inhibits interleukin-2 (IL-2)-driven proliferation 
in T lymphocytes. This leads to a potent immunosuppressive effect. 
Consequently, mTOR inhibitors have been adopted into use as a 
part of immunosuppressive regimens in solid organ transplanta-
tion (82, 83). In addition to the immunosuppressive effects of rapa-
mycin, it has also been shown to induce the preferential growth of 
CD4+CD25+FOXP3+Tregs in vitro (84). Evidence is emerging that 
rapamycin treatment in vitro can also induce CD8+CD28−Tregs in 
murine models (85), indicating that adoptive transfer strategies to 
induce allograft tolerance that are currently under investigation 
for CD4 Tregs could potentially be adjusted for CD8 Tregs.
Another immunosuppressive drug that has been shown to 
be able to induce preferential expansion of CD8 Tregs in vitro is 
CTLA-4-Ig belatacept, a recently approved drug for transplant 
immunosuppression treatment (86). A CTLA-4 antagonist would 
affect the metabolic function of effector CD8 cells by blocking 
CD28 costimulation signaling, which has the downstream effects 
of impeding AKT activation and downregulating glucose and 
glutamine uptake. Additionally, Barbon et  al. showed that by 
first alloanergizing human PBMCs with belatacept and then 
allostimulating the cells caused an increase in the frequency of 
CD8+CD28− T cells. Furthermore, repeated rounds of allores-
timulation after alloanergization would continue to expand the 
CD8+CD28− Tregs, which were able to suppress the proliferation 
of CD4 T cells in a dose-dependent manner (86). Additionally, 
Barbon et  al. reported on three hematopoietic stem cell trans-
plant recipients with a marked increase in blood circulating 
CD8+CD28− T cells between days 20 and 40 post-transplantation 
(86). While these findings are still preliminary, it is promising 
evidence that CD8 Tregs could play a future role in controlling 
allograft rejection.
COnCLUSiOn
When CD8 T cells go from a quiescent to an activated state, 
there are also major alterations to their metabolic programming. 
Upregulation of glycolysis and glutaminolysis has been shown to 
be important not only to fulfill the energy requirements of the 
activated effector CD8 cells but also to provide the biosynthetic 
materials needed for this rapidly expanding population. Research 
into the immunometabolics of CD8 cells not only expands our 
understanding about CD8 T cells but also provides new phar-
maceutical targets that could help to reduce the negative effect of 
these cells in an allograft immune response.
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